XOMA Royalty (XOMA) Competitors $34.20 +1.45 (+4.43%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$34.30 +0.10 (+0.31%) As of 08/22/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XOMA vs. XOMAO, INVA, DVAX, MNKD, OPK, GERN, RIGL, ZBIO, MYGN, and VSTMShould you be buying XOMA Royalty stock or one of its competitors? The main competitors of XOMA Royalty include XOMA (XOMAO), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Geron (GERN), Rigel Pharmaceuticals (RIGL), Zenas BioPharma (ZBIO), Myriad Genetics (MYGN), and Verastem (VSTM). These companies are all part of the "medical" sector. XOMA Royalty vs. Its Competitors XOMA Innoviva Dynavax Technologies MannKind OPKO Health Geron Rigel Pharmaceuticals Zenas BioPharma Myriad Genetics Verastem XOMA Royalty (NASDAQ:XOMA) and XOMA (NASDAQ:XOMAO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability. Is XOMA or XOMAO more profitable? XOMA has a net margin of 0.00% compared to XOMA Royalty's net margin of -27.57%. XOMA Royalty's return on equity of 2.63% beat XOMA's return on equity.Company Net Margins Return on Equity Return on Assets XOMA Royalty-27.57% 2.63% 0.97% XOMA N/A N/A N/A Do institutionals and insiders have more ownership in XOMA or XOMAO? 95.9% of XOMA Royalty shares are held by institutional investors. 9.1% of XOMA Royalty shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor XOMA or XOMAO? In the previous week, XOMA Royalty had 12 more articles in the media than XOMA. MarketBeat recorded 16 mentions for XOMA Royalty and 4 mentions for XOMA. XOMA Royalty's average media sentiment score of 0.55 beat XOMA's score of 0.13 indicating that XOMA Royalty is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XOMA Royalty 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XOMA 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate XOMA or XOMAO? XOMA Royalty presently has a consensus price target of $69.50, suggesting a potential upside of 103.22%. Given XOMA Royalty's stronger consensus rating and higher probable upside, equities research analysts clearly believe XOMA Royalty is more favorable than XOMA.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XOMA Royalty 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67XOMA 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher earnings & valuation, XOMA or XOMAO? XOMA has lower revenue, but higher earnings than XOMA Royalty. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXOMA Royalty$28.49M14.51-$13.82M-$1.55-22.06XOMA$12.77MN/AN/AN/AN/A SummaryXOMA Royalty beats XOMA on 10 of the 11 factors compared between the two stocks. Get XOMA Royalty News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XOMA vs. The Competition Export to ExcelMetricXOMA RoyaltyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$413.41M$3.11B$5.81B$9.76BDividend YieldN/A2.23%4.39%4.06%P/E Ratio-22.0621.0031.3626.05Price / Sales14.51209.44387.8788.42Price / CashN/A44.5038.0259.36Price / Book5.718.129.536.60Net Income-$13.82M-$54.72M$3.26B$265.65M7 Day Performance9.02%2.62%2.14%2.00%1 Month Performance32.51%3.25%3.22%0.46%1 Year Performance21.06%10.82%30.18%18.88% XOMA Royalty Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XOMAXOMA Royalty4.1364 of 5 stars$34.20+4.4%$69.50+103.2%+21.1%$413.41M$28.49M-22.0610Analyst RevisionHigh Trading VolumeXOMAOXOMAN/A$25.46+0.0%N/A+1.1%$0.00$12.77M0.0010Short Interest ↓INVAInnoviva4.5201 of 5 stars$20.78-0.7%$42.75+105.7%+6.9%$1.32B$358.71M67.03100News CoverageAnalyst DowngradeDVAXDynavax Technologies4.509 of 5 stars$10.76-0.3%$24.33+126.1%-8.6%$1.27B$277.25M-23.39350News CoverageAnalyst ForecastMNKDMannKind3.1833 of 5 stars$3.81+2.1%$9.71+155.0%-23.5%$1.14B$285.50M34.64400OPKOPKO Health4.4477 of 5 stars$1.40+2.2%$2.75+96.4%-12.4%$1.09B$664.03M-5.602,997Positive NewsGERNGeron3.1291 of 5 stars$1.44-0.7%$4.19+190.8%-67.8%$925.12M$76.99M-11.08229News CoverageRIGLRigel Pharmaceuticals1.5201 of 5 stars$40.07+1.4%$38.20-4.7%+232.5%$708.70M$179.28M7.41160ZBIOZenas BioPharma1.4786 of 5 stars$17.28+2.7%$36.67+112.2%N/A$708.29M$5M-4.87N/AHigh Trading VolumeMYGNMyriad Genetics3.6162 of 5 stars$5.71flat$12.45+118.1%-78.6%$531.28M$837.60M-1.332,700VSTMVerastem3.0228 of 5 stars$7.97-3.0%$13.29+66.7%+269.1%$505.90M$10K-2.4350 Related Companies and Tools Related Companies XOMA Alternatives Innoviva Alternatives Dynavax Technologies Alternatives MannKind Alternatives OPKO Health Alternatives Geron Alternatives Rigel Pharmaceuticals Alternatives Zenas BioPharma Alternatives Myriad Genetics Alternatives Verastem Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XOMA) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Royalty Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA Royalty With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access